Ignite Creation Date:
2025-12-24 @ 3:05 PM
Ignite Modification Date:
2026-02-22 @ 4:14 PM
Study NCT ID:
NCT02898259
Status:
TERMINATED
Last Update Posted:
2022-09-26
First Post:
2016-09-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma
Sponsor:
Brian Hill
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CASE1414
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | OTHER | View |